Pre-screening | Screening | Baseline | Follow-up | |||
---|---|---|---|---|---|---|
Visit | 1 | 2 | 3 | 4 (phone call only) | ||
Assessmentsa | Within 3 months of baseline visit | Week −4 to −1 | Day 0 | Week 12 (+/− 7 days) | Week 24 (+/− 7 days) | Week 25 (+/− 3 days) |
Identification and initial approach (including provision of PIS) | X | |||||
Eligibility criteria checked (as per routine clinical practice) | X | |||||
Written informed consent (including discussion of study in detail, questions answered) | X | |||||
Physical examination (height,e weight, blood pressure, pulse) | X | X | ||||
Venepuncture | X b | X c | Xd | |||
Clinical history (relevant medical history, medication list/history) | X | |||||
Participant-completed questionnaires (ThyDQoL, ThySRQ, EQ-5D) | X | X | ||||
Nurse-administered questionnaires (FRAT, TUG) | X | X | ||||
Randomization (after all eligibility criteria checked and written informed consent obtained) | X | |||||
Study medication prescribed and dispensed (following LT4 dose assessment at visit 2 only) | X | X | ||||
Study medication compliance checks | X | X | ||||
Concomitant medication | X | X | X | |||
Adverse events | X | X | ||||
Serious adverse events | X | X | X |